QFIN has shed 27% in a single week and nearly 40% over the past month, leaving it trading at $8.38 — a level that makes JP Morgan's freshly cut $9 target look optimistic in retrospect.
The earnings print on August 26 triggered the sharpest single-session move in recent data: the stock fell just over 20% on the day. That followed a sector-wide deterioration already well underway. Close peer LX dropped 32% on the week and FINV lost 24%, confirming the damage is not idiosyncratic. The selloff has now taken QFIN to a trailing one-month loss of nearly 40%, and there is no next earnings date on the calendar to anchor a recovery thesis.
Options positioning has grown more defensive as the stock has fallen. The put/call ratio is running at 0.43, roughly 1.5 standard deviations above its 20-day average of 0.33. That is not an extreme reading — the 52-week high is 1.04 — but the direction of travel matters. The ratio was close to its 52-week low of 0.26 as recently as August 21, meaning demand for downside protection has risen sharply in the week since earnings landed. The short interest picture remains calm by contrast. Availability is extraordinarily loose at 1,807% of estimated short interest, meaning shares available to borrow outnumber shares already borrowed by a factor of more than 18. Borrowing costs at 0.49% annually are negligible. Short positions have grown 26% over the past month but remain at an absolute level — roughly 3.25 million shares — that carries no squeeze risk. The lending market is not telling a story of aggressive conviction from the bear side.
The Street story is now dominated by the JP Morgan downgrade filed the day earnings hit. Katherine Lei moved QFIN from Neutral to Underweight and cut the target from $13.50 to $9.00 — a target that, with the stock at $8.38, already looks almost matched. That move completes a remarkable sequence: the same firm initiated at $65 Overweight in mid-2025, downgraded to Neutral at $21 in November 2025, and has now reached Underweight at $9. Jefferies retains a Buy at $23.40, a target last updated in March 2026 and now sitting nearly three times the current price — a gap that reflects either a deeply contrarian view or a target that has not kept pace with the deterioration. The consensus mean target appears to reflect a data or currency mismatch and should not be taken at face value. Valuation multiples, however, are striking on their own terms: the stock trades at a price-to-book of 0.29 and a P/E of 2.8, with an EV/EBITDA of 1.4. These are distress-level multiples for a company still generating earnings.
Insider activity provides a small counterpoint. Directors bought a net $3.26 million worth of shares in the 90 days to June 9, with purchases at prices of $12.48 and $12.89 — both well above the current level. The activist register is also worth noting: Aerovane Company Limited holds a 17.9% stake filed under Schedule 13D, making it a declared activist. As of last disclosure in December 2025, that position represented over 46 million shares. Stakes disclosed under 13D/G rules are event-driven around the 5% threshold, and holders may reduce below 5% without a further filing, so the current position is unconfirmed. Still, a 17.9% activist stake sitting well underwater adds a layer of structural interest to the story.
The data to watch now is whether options defensive positioning continues to build — the PCR approaching the 0.60–0.70 range would signal genuine fear rather than tactical hedging — and whether any of the larger institutional holders, several of whom added shares through mid-2026, begin to reduce.
See the live data behind this article on ORTEX.
Open QFIN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
